Fig. 8: Loss of TRM phenotype in TDLN stem-like T cells is largely due to type I IFN-dependent adjuvant effects.
From: TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine
a Experimental design. Filled black, PBS; empty black, peptide; blue, poly I:C; aqua, poly I:C + aIFNAR; and red, vaccine. b The percentage of donor Pmel-1 T cells in total TDLN CD8 are shown (PBS, n = 7, peptide, n = 9, poly I:C, n = 8, IFNAR blocking, n = 7 and Vaccine, n = 18). c The percentage of donor Pmel-1 T cells in total CD45+ cells isolated from the tumor are shown (PBS, n = 24, peptide, n = 9, poly I:C, n = 9, IFNAR blocking, n = 9 and Vaccine, n = 13). d The percentage of CD69+CD103+ cells in stem-like Pmel-1 T cells isolated from TDLN are shown (PBS, n = 7, peptide, n = 9, poly I:C, n = 9, IFNAR blocking, n = 8 and Vaccine, n = 9). e Representative FACS profiles of pre-gated stem-like Pmel-1 T cells isolated from TDLN are shown. Each symbol in d represents the results from an individual mouse. Data are presented as mean ± SEM. 2 independent repeats. N.S., not significant (p > 0.05) and indicated p values are calculated by Ordinary one-way ANOVA with multi-comparison posttest. Two-sided tests were used. Source data are provided as a Source data file.
